Philips Shares Jump 6.6% as a DOJ Deal Nears on the Recall

Philips shares jumped 6.6% in early European trading on Tuesday, November 3, after the Dutch health-technology company beat third-quarter profit forecasts and said its Respironics unit had reached an agreement in principle with the U.S. Department of Justice over the sleep-device recall. The company booked a €288 million provision for the proposed settlement, reiterated its full-year outlook, and reported stronger orders and margins — a combination that gave investors the clearest sign yet that the recall chapter is moving toward a close.

What happened

Philips said group sales were €4.4 billion in the third quarter, reflecting 3% comparable sales growth, while comparable order intake rose 8%, driven by Diagnosis & Treatment. Adjusted EBITA rose to €569 million, above the €522 million company-compiled consensus, and the adjusted EBITA margin widened by 70 basis points to 13.0%, with expansion in every segment. The full release is on Philips' own results page.

The legal news mattered as much as the numbers. Philips Respironics reached an agreement in principle with the Department of Justice to resolve previously disclosed criminal and civil investigations related to the Respironics recall. Philips recorded the €288 million provision in the quarter, said the settlement still needs final documentation, and expects payment in the first quarter of 2027. That charge is why reported profit looked weak even as the underlying business beat: income from operations was €165 million, and the Wall Street Journal reported net profit fell to €27 million from €184 million a year earlier.

Why the stock is blowing up

For years, the recall has been the overhang on Philips: an open-ended U.S. investigation means an unknown bill, and markets price unknown bills harshly. An agreement in principle does not end the story, but it replaces an open question with a specific number — €288 million, booked now and expected to be paid in early 2027. As Finimize put it, moving from an open-ended investigation to a defined provision can shrink the uncertainty discount investors apply to the shares.

The trading reaction was immediate. The Journal said shares rose 6.6% in early European trading, and a later quote carried by ad-hoc-news put the stock at €25.84, still 5.43% above Monday's Xetra close of €24.51. Analyst Natalia Webster at RBC Capital Markets, quoted by the Journal, said the margin result quelled concerns about Philips delivering its full-year margin expectations.

The business underneath the headline

The quarter was not only about lawyers. Connected Care comparable sales rose 5% and its adjusted EBITA margin jumped 190 basis points to 13.3%. Personal Health comparable sales rose 8%, with a 17.7% margin. Diagnosis & Treatment sales were flat, as growth in Image Guided Therapy was offset by weaker Precision Diagnosis, including ultrasound phasing and lower sales in China. Operating cash flow was €544 million and free cash flow was €384 million, and Philips said productivity measures delivered €170 million of savings in the quarter.

Chief Executive Roy Jakobs pointed to demand for AI-enabled products, including the new Verida and Rembra CT platforms, the Alturion ultrasound system and the HealthSuite Imaging cloud solution. Philips also noted that it extended a monitoring partnership with one of the largest U.S. health systems through 2034, a reminder that the hospital business kept winning work while the recall case ground on.

What is not settled yet

Readers should keep two caveats in view. First, this is an agreement in principle, not a signed final settlement — Philips itself says it is subject to finalisation of the documentation. Second, Philips' outlook explicitly excludes other ongoing Respironics-related proceedings, including an investigation by U.S. state attorneys general. In the same quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from some investors for a further investigation into Philips over the recall, which removes one more legal thread, but not every thread.

What's next

Philips reiterated its full-year 2026 outlook: comparable sales growth of 3% to 4.5%, an adjusted EBITA margin of 13.5% to 14.0%, and free cash flow of €1.5 billion to €1.7 billion. The next milestones are concrete: final settlement documentation with the Department of Justice, the expected payment in the first quarter of 2027, and whether order growth holds up when Philips next reports. For now, Tuesday's move is the market's verdict on a simple idea — a known €288 million cost is easier to own than an unknown one.

FAQ

Why did Philips shares jump on November 3?
Shares rose 6.6% in early European trading after Philips beat third-quarter adjusted EBITA forecasts and announced an agreement in principle with the U.S. Department of Justice over the Respironics recall investigations.

How much is the proposed DOJ settlement?
Philips recorded a €288 million provision in the third quarter, expects to pay in the first quarter of 2027, and says the deal still needs final documentation.

How did Philips perform in Q3 2026?
Sales were €4.4 billion with 3% comparable growth, order intake rose 8%, and adjusted EBITA was €569 million at a 13.0% margin, above the €522 million consensus.

Is the recall case fully over for Philips?
No. The DOJ agreement is in principle only, and Philips says its outlook excludes other proceedings, including a U.S. state attorneys general investigation.